electroCore, Inc. ECOR
7.71 USD -0.01 (-0.13%)
At closeNov 11, 2026, 4:00 PM EST
7.71 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
7.65 Day range 8.32
4.42 52-week range 12.29
- YTD
- +71.71%
- 1 year
- +22.38%
News
zacks.com electroCore (ECOR) Upgraded to Buy: Here's What You Should Know electroCore (ECOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in…
seekingalpha.com electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript electroCore, Inc. (ECOR) Q3 2026 Earnings Call Transcript
zacks.com electroCore, Inc. (ECOR) Reports Q3 Loss, Misses Revenue Estimates electroCore, Inc. (ECOR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.4 per share a year ago.
marketbeat.com electroCore Q3 Earnings Call Highlights electroCore NASDAQ: ECOR reported record third-quarter sales and a narrower loss, but revised its 2026 revenue outlook as changes to its sales organization took longer than expected to reach the full…
benzinga.com CORRECTION: electroCore Widens FY2026 Sales Guidance from $41.600M to $39.000M-$42.000M vs $41.915M Est electroCore (NASDAQ:ECOR) widens FY2026 sales outlook from $41.600 million to $39.000 million-$42.000 million vs $41.915 million estimate.
benzinga.com electroCore Q3 2026 Earnings Call Transcript electroCore (NASDAQ:ECOR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com electroCore Raises FY2026 Sales Guidance from $41.600M to $41.642M vs $41.915M Est electroCore (NASDAQ:ECOR) raises FY2026 sales outlook from $41.600 million to $41.642 million vs $41.915 million estimate.
benzinga.com electroCore Q3 EPS $(0.13) Beats $(0.27) Estimate, Sales $9.690M Miss $10.928M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 67.5 percent increase over losses of $(0.40)…
globenewswire.com electroCore Announces Third Quarter 2026 Financial Results Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss…
globenewswire.com electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026 ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial…
marketbeat.com electroCore Targets 2027 EBITDA Profit as VA, Quell and CIPN Opportunities Expand Joshua Lev, co-CEO, president and CFO of electroCore NASDAQ: ECOR, said the commercial-stage bioelectronic health and wellness company is seeking to broaden its federal-market presence, expand…- benzinga.com electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy electroCore, Inc. (NASDAQ:ECOR), ("electroCore" or the "Company"), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug
globenewswire.com electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN) ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), (“electroCore” or the “Company”), a bioelectronic technology company, today announced that it has submitted a…
defenseworld.net electroCore (NASDAQ:ECOR) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened electroCore, Inc. (NASDAQ: ECOR - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $7.70 and traded as high…
globenewswire.com fMRI Study Suggests Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) Accelerates Neural Processes in Visual Skill Learning ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced…
globenewswire.com electroCore to Present at Planet MicroCap Toronto 2026 powered by MicroCapClub ROCKAWAY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at…
defenseworld.net electroCore (NASDAQ:ECOR) and Enovis (NYSE:ENOV) Head-To-Head Comparison electroCore (NASDAQ: ECOR - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
seekingalpha.com electroCore Has A Line Of Sight At Cash Breakeven electroCore is showing operational and financial improvement, driven by sales force expansion and strong Quell Fibromyalgia growth. ECOR targets >30% FY26 revenue growth, 85%+ gross margins, and…
defenseworld.net Thomas Errico Purchases 5,000 Shares of electroCore (NASDAQ:ECOR) Stock electroCore, Inc. (NASDAQ: ECOR - Get Free Report) Director Thomas Errico bought 5,000 shares of the company's stock in a transaction dated Monday, September 14th. The stock was bought at an average…
zacks.com electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar? electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
benzinga.com Full Transcript: electroCore Q2 2026 Earnings Call electroCore (NASDAQ:ECOR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
globenewswire.com electroCore to Participate at H.C. Wainwright Global Investment Conference ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate…
benzinga.com electroCore Appoints Joshua Lev, Mike Fox As Co-CEOs, Effective Sept. 8 electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed…
globenewswire.com electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation…
globenewswire.com electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's…
seekingalpha.com electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
benzinga.com electroCore Lowers FY2026 Sales Guidance from $41.642M to $41.600M vs $41.921M Est electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41.921 million estimate.- benzinga.com electroCore Q2 EPS $(0.33) Beats $(0.40) Estimate, Sales $9.450M Miss $9.491M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 25 percent increase over losses of $(0.44) per…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock…
- benzinga.com electroCore Announces Publication Of New Clinical Findings For Quell Device, A Wearable Stimulation Device For The Treatment Of Fibromyalgia The publication in JAMA Network Open, titled, "Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial."The study evaluated…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com electroCore Affirms FY2026 Sales Guidance of $41.642M vs $41.957M Est electroCore (NASDAQ:ECOR) affirms FY2026 sales outlook from $41.642 million to $41.642 million vs $41.957 million estimate.
benzinga.com electroCore Q1 EPS $(0.59) Misses $(0.51) Estimate, Sales $9.584M Beat $9.012M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.51) by 15.69 percent. This is a 25.53 percent decrease over losses of…
benzinga.com electroCore Announces New Clinical Findings Published That Demonstrates Potential Benefits Of Adjunctive Non-invasive Vagus Nerve Stimulation In Patients With Chronic Mild Traumatic Brain Injury And Comorbid Post-traumatic Stress Disorder The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with…
benzinga.com electroCore Announces Issuance Of Two New Additions To U.S. Patent Portfolio U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026U.S. Patent No. 12,213,795, entitled "Devices and Methods for Remote Therapy and…- benzinga.com Earnings Scheduled For March 26, 2026
benzinga.com electroCore Q4 EPS $(0.34) Beats $(0.41) Estimate, Sales $9.200M Beat $9.039M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 15 percent increase over losses of $(0.40)…- benzinga.com ElectroCore CEO Dan Goldberger To Retire On April 1; Joshua Lev Appointed Interim President, CFO; Michael Fox Appointed COO electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results.Announced Chief Executive Officer, Dan…
- benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com HC Wainwright & Co. Maintains Buy on electroCore, Lowers Price Target to $18 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a Buy and lowers the price target from $25 to $18.- benzinga.com electroCore Announces Acacia Clinics And The Vagus Nerve Society Launch New Research Initiative To Mull Gammacore Sapphire Use As Treatment For Symptoms Associated With PTSD electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research…
- benzinga.com electroCore Anticipates Reporting FY25 Revenue Of ~$31.8M-$32M; Estimates Q4 Revenue To Be ~$9M-$9.2M Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over…
- benzinga.com ElectroCore Granted Patent # US 12469610 B2 For "SYSTEMS AND METHODS FOR TREATING BLOOD CLOTS WITH NERVE STIMULATION" https://ppubs.uspto.gov/api/pdf/downloadPdf/12469610?requestToken=eyJzdWIiOiIzZTQ5MWI5NS0wZjI4LTQwYjQtOGIyNS05ZmVhNTU3MDU1MjYiLCJ2ZXIiOiJmYWMyMzBiNS1kYjU1LTQwZjMtYTA3Yi1lZTY3MjNlY2U5ZDAiLCJleHAiOjB9
- benzinga.com electroCore Q3 EPS $(0.40), Inline, Sales $8.700M Beat $7.843M Estimate electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 29.03 percent decrease over losses of $(0.31) per share from the same…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com electroCore Announces Its GammaCore Sapphire Non-Invasive Vagus Nerve Stimulation Device Has Been Included In Long-Term Reimbursement Policy By Belgium's National Institute For Health And Disability Insurance electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session